What is HC Wainwright’s Estimate for BDTX Q2 Earnings?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Analysts at HC Wainwright decreased their Q2 2026 earnings per share (EPS) estimates for Black Diamond Therapeutics in a research report issued on Friday, May 8th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.19) for the quarter, down from their prior estimate of ($0.18). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.75) EPS.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02.

A number of other equities analysts have also weighed in on BDTX. Weiss Ratings upgraded Black Diamond Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, April 21st. Wedbush increased their target price on Black Diamond Therapeutics from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Wall Street Zen lowered Black Diamond Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Piper Sandler lowered their price objective on Black Diamond Therapeutics from $9.00 to $8.00 and set an “overweight” rating on the stock in a research note on Friday, January 16th. Finally, BTIG Research raised their price objective on Black Diamond Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Black Diamond Therapeutics Trading Down 1.7%

Shares of NASDAQ BDTX opened at $2.94 on Tuesday. The firm has a market cap of $168.46 million, a P/E ratio of -3.82 and a beta of 3.34. Black Diamond Therapeutics has a 1-year low of $1.68 and a 1-year high of $4.94. The business’s 50 day moving average is $2.50 and its 200-day moving average is $2.82.

Hedge Funds Weigh In On Black Diamond Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its stake in Black Diamond Therapeutics by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 505,780 shares of the company’s stock worth $1,229,000 after acquiring an additional 5,257 shares during the period. Engineers Gate Manager LP increased its stake in Black Diamond Therapeutics by 48.9% during the 4th quarter. Engineers Gate Manager LP now owns 19,701 shares of the company’s stock worth $48,000 after acquiring an additional 6,469 shares during the period. Kathmere Capital Management LLC increased its stake in Black Diamond Therapeutics by 31.0% during the 4th quarter. Kathmere Capital Management LLC now owns 31,822 shares of the company’s stock worth $77,000 after acquiring an additional 7,539 shares during the period. Bank of America Corp DE increased its stake in shares of Black Diamond Therapeutics by 22.5% in the 3rd quarter. Bank of America Corp DE now owns 43,359 shares of the company’s stock valued at $164,000 after purchasing an additional 7,972 shares during the last quarter. Finally, Cerity Partners LLC bought a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at $26,000. Institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.